Theragent and CellVax Therapeutics have reported the initial dosing of a patient in their Phase 2 study of FK-PC101, a new personalized cancer immunotherapy.

Osimertinib mesylate is a small molecule drug that targets EGFR L858R, EGFR T790M, and EGFR-Ex19del.

Allogene Therapeutics shared promising Phase 1 results showcasing ALLO-316's potential in advanced renal cell carcinoma patients at SITC and IKCS.

Eculizumab is a humanized monoclonal antibody that targets the complement protein C5. Developed by Alexion Pharmaceuticals.

Fate Therapeutics Shares Preclinical Data on FT836, a MICA/B-targeted CAR T-cell, at 2024 SITC Meeting.

NDI-101150 is a small molecule drug developed by Nimbus Therapeutics LLC, aimed at targeting the HPK1 protein.

Myeloid Therapeutics to Present on MT-303, a Pioneering mRNA CAR Targeting GPC3 in Advanced HCC, at SITC 2024.

In 2023, the global market for AAV (Adeno-associated virus) therapies reached $1.5 billion, with projections suggesting growth to $22.3 billion by 2029.

OncoResponse Reports Phase 1 Findings of OR502, an anti-LILRB2 Antibody, in Patients with Advanced Cancer.

Eteplirsen, developed by Sarepta Therapeutics, is an antisense oligonucleotide that targets the dystrophin gene.

Harbour BioMed has filed an IND application for HBM9378/SKB378 to treat chronic obstructive pulmonary disease.

Elacestrant hydrochloride is a small molecule drug that targets ERα and is used in the treatment of various therapeutic areas.